GlassScriptPhysician profile
Thaddeus H Riley
NPI 1104874031
$6,805.58
in general payments reported to CMS, 2019-2025
54 companies · $45.66 in 2025
The $45.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,680 · 2020: $989 · 2021: $896 · 2022: $995 · 2023: $1,200 · 2025: $45.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,371.45 | 2019 | |
| Abbvie INC. | $724.66 | 2021-2023 | Vraylar, Linzess |
| Amgen INC. | $684.88 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $561.87 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.41 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $268.21 | 2021-2023 | |
| Glaxosmithkline, LLC. | $230.59 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $226.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $176.27 | 2019-2022 | |
| Novo Nordisk INC | $154.68 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $149.01 | 2020-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $147.61 | 2019-2021 | |
| Atricure, INC. | $144.75 | 2022 | |
| Lilly USA, LLC | $143.87 | 2021-2023 | Mounjaro, Jardiance |
| Tris Pharma INC | $120.87 | 2023 | Dyanavel Xr |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.